Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells

Breast Cancer Research

Volumn 15, Issue 6, 2013, Pages

  Hugo, Honor J ^a   Pereira, Lloyd ^b,c   Suryadinata, Randy ^a   Drabsch, Yvette ^d,g   Gonda, Thomas J ^d   Gunasinghe, N P A Devika ^c,f   Pinto, Cletus ^a,c   Soo, Eliza T L ^a,c   van Denderen, Bryce J W ^a,c   Hill, Prue ^c   Ramsay, Robert G ^b,c   Sarcevic, Boris ^a,c   Newgreen, Donald F ^e   Thompson, Erik W ^a,c  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f UNIVERSITY OF PERADENIYA   (Sri Lanka)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; EPIDERMAL GROWTH FACTOR; FIZZY RELATED PROTEIN; PROTEIN MYB; SULFORHODAMINE B; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; VIMENTIN; HOMEODOMAIN PROTEIN; PROTEIN C MYB; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; ZEB1 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; CELL HYPOXIA; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CHROMATIN IMMUNOPRECIPITATION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; EXPRESSION VECTOR; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; LYMPH NODE METASTASIS; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REPRESSOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE METASTASIS; WESTERN BLOTTING; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

BREAST NEOPLASMS; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYB; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 84896711564     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3580     Document Type: Article

References (79)

1. Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 2011, 27:347-376. 10.1146/annurev-cellbio-092910-154036, 21740232.
2. Said NA, Williams ED. Growth factors in induction of epithelial-mesenchymal transition and metastasis. Cells Tissues Organs 2011, 193:85-97. 10.1159/000320360, 21051862.
3. Gunasinghe NPAD, Thompson EW, Hugo HJ. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Ca Met Rev 2012, 31:469-478.
4. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008, 9:582-589. 10.1038/embor.2008.74, 2396950, 18483486.
5. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer 2007, 7:415-428. 10.1038/nrc2131, 17508028.
6. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 2007, 213:374-383. 10.1002/jcp.21223, 17680632.
7. Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, Berx G, Cano A, Beug H, Foisner R. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005, 24:2375-2385. 10.1038/sj.onc.1208429, 15674322.
8. Aigner K, Descovich L, Mikula M, Sultan A, Dampier B, Bonne S, van Roy F, Mikulits W, Schreiber M, Brabletz T, Sommergruber W, Schweifer N, Wernitznig A, Beug H, Foisner R, Eger A. The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. FEBS Lett 2007, 581:1617-1624. 10.1016/j.febslet.2007.03.026, 2938730, 17391671.
9. Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, Mikulits W, Brabletz T, Strand D, Obrist P, Sommergruber W, Schweifer N, Wernitznig A, Beug H, Foisner R, Eger A. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 2007, 26:6979-6988. 10.1038/sj.onc.1210508, 2899859, 17486063.
10. Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A, Hlubek F, Jung A, Strand D, Eger A, Kirchner T, Behrens J, Brabletz T. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 2008, 68:537-544. 10.1158/0008-5472.CAN-07-5682, 18199550.
11. Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, Neve RM, Thompson EW. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis 2008, 25:629-642. 10.1007/s10585-008-9170-6, 18461285.
12. Blick T, Hugo H, Widodo E, Waltham M, Pinto C, Mani SA, Weinberg RA, Neve RM, Lenburg ME, Thompson EW. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 2010, 15:235-252. 10.1007/s10911-010-9175-z, 20521089.
13. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
14. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer 2008, 8:523-534. 10.1038/nrc2439, 18574464.
15. Zhou Y, Ness SA. Myb proteins: angels and demons in normal and transformed cells. Front Biosci 2011, 16:1109-1131.
16. Drabsch Y, Hugo H, Zhang R, Dowhan DH, Miao YR, Gewirtz AM, Barry SC, Ramsay RG, Gonda TJ. Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells. Proc Natl Acad Sci USA 2007, 104:13762-13767. 10.1073/pnas.0700104104, 1959456, 17690249.
17. Drabsch Y, Robert RG, Gonda TJ. MYB suppresses differentiation and apoptosis of human breast cancer cells. Breast Cancer Res 2010, 12:R55. 10.1186/bcr2614, 2949644, 20659323.
18. Miao RY, Drabsch Y, Cross RS, Cheasley D, Carpinteri S, Pereira L, Malaterre J, Gonda TJ, Anderson RL, Ramsay RG. MYB is essential for mammary tumorigenesis. Cancer Res 2011, 71:7029-7037. 10.1158/0008-5472.CAN-11-1015, 21948968.
19. Postigo AA, Sheppard AM, Mucenski ML, Dean DC. c-Myb and Ets proteins synergize to overcome transcriptional repression by ZEB. EMBO J 1997, 16:3924-3934. 10.1093/emboj/16.13.3924, 1170016, 9233802.
20. Kurima K, Hertzano R, Gavrilova O, Monahan K, Shpargel KB, Nadaraja G, Kawashima Y, Lee KY, Ito T, Higashi Y, Eisenman DJ, Strome SE, Griffith AJ. A noncoding point mutation of Zeb1 causes multiple developmental malformations and obesity in Twirler mice. PLoS Genet 2011, 7:e1002307. 10.1371/journal.pgen.1002307, 3183090, 21980308.
21. Postigo AA, Dean DC. Independent repressor domains in ZEB regulate muscle and T-cell differentiation. Mol Cell Biol 1999, 19:7961-7971. 84881, 10567522.
22. Browne G, Sayan AE, Tulchinsky E. ZEB proteins link cell motility with cell cycle control and cell survival in cancer. Cell Cycle 2010, 9:886-891. 10.4161/cc.9.5.10839, 20160487.
23. Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S, Jung A, Kirchner T, Brabletz T. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006, 131:830-840. 10.1053/j.gastro.2006.06.016, 16952552.
24. Rubio CA. Further studies on the arrest of cell proliferation in tumor cells at the invading front of colonic adenocarcinoma. J Gastroenterol Hepatol 2007, 22:1877-1881. 10.1111/j.1440-1746.2007.04839.x, 17914963.
25. Kent OA, Mullendore M, Wentzel EA, Lopez-Romero P, Tan AC, Alvarez H, West K, Ochs MF, Hidalgo M, Arking DE, Maitra A, Mendell JT. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther 2009, 8:2013-2024. 10.4161/cbt.8.21.9685, 2824894, 20037478.
26. Xia W, Li J, Chen L, Huang B, Li S, Yang G, Ding H, Wang F, Liu N, Zhao Q, Fang T, Song T, Wang T, Shao N. MicroRNA-200b regulates cyclin D1 expression and promotes S-phase entry by targeting RND3 in HeLa cells. Mol Cell Biochem 2010, 344:261-266. 10.1007/s11010-010-0550-2, 20683643.
27. Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, Martinvalet D, Song E, Lim B, Lieberman J. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 2009, 4:e7181. 10.1371/journal.pone.0007181, 2749331, 19787069.
28. Hu F, Wang C, Du J, Sun W, Yan J, Mi D, Zhang J, Qiao Y, Zhu T, Yang S. DeltaEF1 promotes breast cancer cell proliferation through down-regulating p21 expression. Biochim Biophys Acta 1802, 2010:301-312.
29. Fontemaggi G, Gurtner A, Strano S, Higashi Y, Sacchi A, Piaggio G, Blandino G. The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation. Mol Cell Biol 2001, 21:8461-8470. 10.1128/MCB.21.24.8461-8470.2001, 100009, 11713281.
30. Ackland ML, Michalczyk A, Whitehead RH. PMC42, a novel model for the differentiated human breast. Exp Cell Res 2001, 263:14-22. 10.1006/excr.2000.5106, 11161701.
31. Ackland ML, Newgreen DF, Fridman M, Waltham MC, Arvanitis A, Minichiello J, Price JT, Thompson EW. Epidermal growth factor-induced epithelio-mesenchymal transition in human breast carcinoma cells. Lab Invest 2003, 83:435-448. 10.1097/01.LAB.0000059927.97515.FD, 12649344.
32. Hugo HJ, Kokkinos MI, Blick T, Ackland ML, Thompson EW, Newgreen DF. Defining the E-cadherin repressor interactome in epithelial-mesenchymal transition: the PMC42 model as a case study. Cells Tissues Organs 2011, 193:23-40. 10.1159/000320174, 21051859.
33. Whitehead RH, Bertoncello I, Webber LM, Pedersen JS. A new human breast carcinoma cell line (PMC42) with stem cell characteristics. I. Morphologic characterization. J Natl Cancer Inst 1983, 70:649-661.
34. Whitehead RH, Monaghan P, Webber LM, Bertoncello I, Vitali AA. A new human breast carcinoma cell line (PMC42) with stem cell characteristics. II. Characterization of cells growing as organoids. J Natl Cancer Inst 1983, 71:1193-1203.
35. Whitehead RH, Quirk SJ, Vitali AA, Funder JW, Sutherland RL, Murphy LC. A new human breast carcinoma cell line (PMC42) with stem cell characteristics. III. Hormone receptor status and responsiveness. J Natl Cancer Inst 1984, 73:643-648.
36. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007, 4:359-365. 10.1038/nmeth1015, 2933182, 17396127.
37. Barry SC, Harder B, Brzezinski M, Flint LY, Seppen J, Osborne WR. Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression. Hum Gene Ther 2001, 12:1103-1108. 10.1089/104303401750214311, 11399231.
38. Skalamera D, Ranall MV, Wilson BM, Leo P, Purdon AS, Hyde C, Nourbakhsh E, Grimmond SM, Barry SC, Gabrielli B, Gonda TJ. A high-throughput platform for lentiviral overexpression screening of the human ORFeome. PLoS One 2011, 6:e20057. 10.1371/journal.pone.0020057, 3101218, 21629697.
39. Hugo HJ, Wafai R, Blick T, Thompson EW, Newgreen DF. Staurosporine augments EGF-mediated EMT in PMC42-LA cells through actin depolymerisation, focal contact size reduction and Snail1 induction: a model for cross-modulation. BMC Cancer 2009, 9:235. 10.1186/1471-2407-9-235, 2717979, 19604397.
40. Kaproth-Joslin KA, Li X, Reks SE, Kelley GG. Phospholipase C delta 1 regulates cell proliferation and cell-cycle progression from G1- to S-phase by control of cyclin E-CDK2 activity. Biochem J 2008, 415:439-448. 10.1042/BJ20080233, 18588506.
41. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006, 1:2315-2319. 10.1038/nprot.2006.339, 17406473.
42. Hammacher A, Thompson EW, Williams ED. Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer. Int J Biochem Cell Biol 2005, 37:442-450. 10.1016/j.biocel.2004.07.011, 15474988.
43. Voigt W. Sulforhodamine B assay and chemosensitivity. Methods Mol Med 2005, 110:39-48.
44. Hugo H, Cures A, Suraweera N, Drabsch Y, Purcell D, Mantamadiotis T, Phillips W, Dobrovic A, Zupi G, Gonda TJ, Iacopetta B, Ramsay RG. Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers. Genes Chromosomes Cancer 2006, 45:1143-1154. 10.1002/gcc.20378, 16977606.
45. Escriva M, Peiro S, Herranz N, Villagrasa P, Dave N, Montserrat-Sentis B, Murray SA, Franci C, Gridley T, Virtanen I, García de Herreros A. Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol 2008, 28:1528-1540. 10.1128/MCB.02061-07, 2258777, 18172008.
46. Hu F, Wang C, Guo S, Sun W, Mi D, Gao Y, Zhang J, Zhu T, Yang S. deltaEF1 promotes osteolytic metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression. Biochim Biophys Acta 1809, 2011:200-210.
47. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006, 1:1112-1116. 10.1038/nprot.2006.179, 17406391.
48. Jo M, Lester RD, Montel V, Eastman B, Takimoto S, Gonias SL. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem 2009, 284:22825-22833. 10.1074/jbc.M109.023960, 2755690, 19546228.
49. Lester RD, Jo M, Montel V, Takimoto S, Gonias SL. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol 2007, 178:425-436. 10.1083/jcb.200701092, 2064849, 17664334.
50. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96. 10.1186/1471-2164-7-96, 1468408, 16643655.
51. Aokage K, Ishii G, Ohtaki Y, Yamaguchi Y, Hishida T, Yoshida J, Nishimura M, Nagai K, Ochiai A. Dynamic molecular changes associated with epithelial-mesenchymal transition and subsequent mesenchymal-epithelial transition in the early phase of metastatic tumor formation. Int J Cancer 2011, 128:1585-1595. 10.1002/ijc.25500, 20533280.
52. Gavert N, Ben-Ze'ev A. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med 2008, 14:199-209. 10.1016/j.molmed.2008.03.004, 18406208.
53. Thorner AR, Parker JS, Hoadley KA, Perou CM. Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer. PLoS One 2010, 5:e13073. 10.1371/journal.pone.0013073, 2951337, 20949095.
54. Nicolaides NC, Gualdi R, Casadevall C, Manzella L, Calabretta B. Positive autoregulation of c-myb expression via Myb binding sites in the 5′ flanking region of the human c-myb gene. Mol Cell Biol 1991, 11:6166-6176. 361795, 1944282.
55. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003, 5:R217-R222. 10.1186/bcr651, 314411, 14580257.
56. Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 2010, 9:179. 10.1186/1476-4598-9-179, 2907333, 20609236.
57. Valdes F, Alvarez AM, Locascio A, Vega S, Herrera B, Fernandez M, Benito M, Nieto MA, Fabregat I. The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor beta in fetal rat hepatocytes. Mol Cancer Res 2002, 1:68-78.
58. Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 2005, 132:3151-3161. 10.1242/dev.01907, 15983400.
59. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292. 10.1016/j.cell.2011.09.024, 3261217, 22000009.
60. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008, 14:818-829. 10.1016/j.devcel.2008.05.009, 18539112.
61. Quintana AM, Liu F, O'Rourke JP, Ness SA. Identification and regulation of c-Myb target genes in MCF-7 cells. BMC Cancer 2011, 11:30. 10.1186/1471-2407-11-30, 3038977, 21261996.
62. Yori JL, Johnson E, Zhou G, Jain MK, Keri RA. Kruppel-like factor 4 inhibits epithelial-to-mesenchymal transition through regulation of E-cadherin gene expression. J Biol Chem 2011, 285:16854-16863.
63. Ahn YH, Gibbons DL, Chakravarti D, Creighton CJ, Rizvi ZH, Adams HP, Pertsemlidis A, Gregory PA, Wright JA, Goodall GJ, Flores ER, Kurie JM. ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Invest 2012, 122:3170-3183. 10.1172/JCI63608, 3428095, 22850877.
64. Karafiat V, Dvorakova M, Krejci E, Kralova J, Pajer P, Snajdr P, Mandikova S, Bartunek P, Grim M, Dvorak M. Transcription factor c-Myb is involved in the regulation of the epithelial-mesenchymal transition in the avian neural crest. Cell Mol Life Sci 2005, 62:2516-2525. 10.1007/s00018-005-5297-7, 16231084.
65. Tanno B, Sesti F, Cesi V, Bossi G, Ferrari-Amorotti G, Bussolari R, Tirindelli D, Calabretta B, Raschella G. Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin. J Biol Chem 2011, 285:29434-29445.
66. Knopfova L, Beneš P, Pekarčíková L, Hermanová M, Masařík M, Pernicová Z, Souček K, Šmarda J. c-Myb regulates matrix metalloproteinases 1/9, and cathepsin D: implications for matrix-dependent breast cancer cell invasion and metastasis. Mol Cancer 2012, 11:15. 10.1186/1476-4598-11-15, 3325857, 22439866.
67. Cesi V, Casciati A, Sesti F, Tanno B, Calabretta B, Raschella G. TGF-beta-induced c-Myb affects the expression of EMT-associated genes and promotes invasion of ER + breast cancer cells. Cell Cycle 2011, 10:4149-4161. 10.4161/cc.10.23.18346, 22101269.
68. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 2010, 107:15449-15454. 10.1073/pnas.1004900107, 2932589, 20713713.
69. Mayes DA, Hu Y, Teng Y, Siegel E, Wu X, Panda K, Tan F, Yung WK, Zhou YH. PAX6 suppresses the invasiveness of glioblastoma cells and the expression of the matrix metalloproteinase-2 gene. Cancer Res 2006, 66:9809-9817. 10.1158/0008-5472.CAN-05-3877, 17047041.
70. Zong X, Yang H, Yu Y, Zou D, Ling Z, He X, Meng X. Possible role of Pax-6 in promoting breast cancer cell proliferation and tumorigenesis. BMB Rep 2011, 44:595-600. 10.5483/BMBRep.2011.44.9.595, 21944253.
71. Malaterre J, Mantamadiotis T, Dworkin S, Lightowler S, Yang Q, Ransome MI, Turnley AM, Nichols NR, Emambokus NR, Frampton J, Ramsay RG. c-Myb is required for neural progenitor cell proliferation and maintenance of the neural stem cell niche in adult brain. Stem Cells 2008, 26:173-181. 10.1634/stemcells.2007-0293, 17901403.
72. Labelle M, Schnittler HJ, Aust DE, Friedrich K, Baretton G, Vestweber D, Breier G. Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling. Cancer Res 2008, 68:1388-1397. 10.1158/0008-5472.CAN-07-2706, 18316602.
73. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Ramsay RG. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
74. Dave B, Mittal V, Tan NM, Chang JC. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 2012, 14:202. 3496111, 22264257.
75. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 2009, 15:195-206. 10.1016/j.ccr.2009.01.023, 19249678.
76. Wu Y, Zhou BP. Snail: more than EMT. Cell Adh Migr 2010, 4:199-203. 10.4161/cam.4.2.10943, 2900613, 20168078.
77. Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target?. Nat Rev Cancer 2010, 10:871-877. 10.1038/nrc2933, 21048784.
78. Perret GY, Uzzan B. An anticancer strategic dilemma: to kill or to contain: the choice of the pharmaceutical industry in 2009. Fundam Clin Pharmacol 2011, 25:283-295. 10.1111/j.1472-8206.2010.00849.x, 20608993.
79. Pieraccioli M, Imbastari F, Antonov A, Melino G, Raschella G. Activation of miR200 by c-Myb depends on ZEB1 expression and miR200 promoter methylation. Cell Cycle 2013, 12:1-12. 10.4161/cc.23067, 3570496, 23255116.